Transplant Biomedicals is a European company based in Barcelona aimed at developing novel medical strategies to improve organ, tissue and cellular preservation to overall enhance patients´ wellness.
Our values are at the basis of all our organizations actions
- Fight for our cause, the patient
- Trust and commitment
- Innovation, entrepreneurship, creativity and passion
- Superior quality that meets needs and provides sustainable added value
Products
Transplant Biomedicals is developing a new organ transport device available for hospital use. The device uses a revolutionary technology leading to superior preservation of the organs during transport from the donor hospital to the transplant center.
Our high quality and convenient product aims to become the global gold standard for transplant centers by reducing the risk of delayed graft function, improving graft survival and as such leading to better patient outcomes. In addition, our product has the potential to use part of the marginal organs that are currently discarded and thus reduce the waiting lists. [3D conceptual model]
“At Transplant Biomedicals team we are excited to solve the most ambitious challenges of health professionals and, therefore, we transform scientific and technological knowledge into products that contribute to the improvement of people’s health.”
Joan Salgado – Chief Executive Officer
Team
Joan Salgado, PhD
Chief Executive Officer
20 years of experience in the pharmaceutical industry in project management roles ranging from R&D to commercialization of new drugs at worldwide level. In the last 12 years, his focus has been on innovative Medical Device development and commercialization. Seven years of experience in academic research.
More information: LinkedIn
Dr. Carmen Peralta
Chief Scientific Officer
Dr. Peralta is co-founder of Transplant Biomedicals. She is Senior Group Leader at IDIBAPS. Her expertise focuses in pharmacological and surgical strategies aimed at reducing hepatic ischemia/reperfusion injury associated with hepatic resections and liver transplantation.
More information: LinkedIn
Miguel Ángel Gómez
Chief Technology Officer
Mr. Miguel Ángel Gómez has more than 20 years of experience in the development of medical devices in management positions in I&D, quality, regulation and production.
Jordi Petit, MBA
Chief Financial Officer
Mr. Petit has worked during more than 25 years in different financial directive positions in both multinational and start-ups of recent creation in the life science sector.
More information: LinkedIn
Montse Gutiérrez
QA&RA Manager
Ms. Montse Gutiérrez has an extensive knowledge in Quality and Regulatory Affairs in Medical Device due to over more than 12 years of experience in a Notified Body as Auditor and Technical Director and during the last 5 years in the electromedicine, cosmetic and dental industry.
More information: LinkedIn
Diana Villanueva
Clinical Operations Manager
Mrs. Diana Villanueva is Biologist, Master in Clinical Research and has more than 13 years of experience in different companies dedicated to the realization of clinical clinics for the pharmaceutical industry.
Board of Directors
Advisory Board
Investors
Transplant Biomedicals is backed by specialized national venture capital. These investors include Caixa Capital Risc and Kereon Partners and several private investors. To date, Transplant Biomedicals has raised over €4M.
Partners
Contact
Transplant Biomedicals S.L.
Marie Curie, 8-14
Barcelona Advanced Industry Park
08042 Barcelona [Spain]
Marie Curie, 8-14
Barcelona Advanced Industry Park
08042 Barcelona [Spain]
+34 935 27 27 20
Investors
January 2th 2017
Transplant Biomedicals closes €2.5M in Series A financing by Caixa Capital Risc and Kereon Partners. More information
November 11th 2016
Transplant Biomedicals raises €1.5M. More information.
If you want to invest in Transplant Biomedicals, please email us at: info@transplantbiomed.com
Relevant milestone achieved by @TBiomedicals Thanks to the families involved in the donation process, patients, transplantation units, and their staff for completing the enrolment of EMERGE study: @hospitalclinic, @vallhebron, @hbellvitge, @idibaps biotech-spain.com/en/articles/tr…
Els trasplantaments d'òrgans augmenten un 18% el primer trimestre del 2019 ara.cat/_84215aa2?s=t vía @ARAsocietat
